Leica Biosystems

What Leica Biosystems does

Leica Biosystems, headquartered in Nußloch, Germany with US operations centered in Deer Park, IL and Vista, CA, is a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR) that develops end-to-end anatomic pathology workflow solutions for cancer diagnostics. The company traces its heritage to Rudolf Jung's 1872 founding of R. Jung in Heidelberg and was established as a distinct entity within Danaher in 2011. It operates through three business units — Core Histology, Advanced Staining, and Pathology Imaging — supported by seven ISO 13485-certified manufacturing sites across Germany, the UK, the Netherlands, Australia, China, and the United States, and a commercial footprint spanning 30+ countries.

Its core products span the full anatomic pathology chain: biopsy (Mammotome), tissue processing (HistoCore PEGASUS, PELORIS, PEARL), sectioning (HistoCore microtomes and cryostats), staining (BOND-III, BOND-MAX, BOND-PRIME, BOND RX for IHC/ISH/multiplex), slide labeling (Leica IP S/C, HistoCore PERMA S), and digital pathology (Aperio scanner family including the FDA-cleared GT 450 DX, GT 180 DX, CS5 DX, and GT Elite at 103 slides/hour). AI capability is delivered through Aperio iQC quality control, the Aperio HALO AP image management system, the Aperio AI Store marketplace, and integration with L7|ESP informatics. The company claims the largest digital pathology instrument install base worldwide, supports nearly 2 million cancer tests weekly, is trusted by 100% of the Top 50 Hospitals for Cancer, and holds approximately 25% of the global digital pathology market per QYResearch.

Leica generates revenue across six streams: capital equipment (hardware sales), histology and IHC consumables (recurring), IHC primary antibodies and detection systems (recurring), digital pathology software and AI subscriptions (recurring/licensing), companion diagnostic (CDx) development and commercialization with biopharma (professional services), and service/support contracts. Pricing is quote-based and not publicly disclosed. GTM combines direct enterprise sales, a self-serve e-commerce shop, authorized reseller channels (e.g., Mindpeak), and biopharma CDx partnerships (AstraZeneca/Daiichi Sankyo, CellCarta, Lunit/Indica Labs, Paige). Key customers include the Top 50 Hospitals for Cancer, Leeds Teaching Hospitals NHS Trust (part of the UK's National Pathology Imaging Co-operative), Kurume University, University Hospitals Cleveland, and the named biopharma CDx partners.

Name

Leica Biosystems

Legal name

Leica Biosystems Nussloch GmbH

Website

https://leicabiosystems.com

Company type

Private

Founded year

1872

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Leica Biosystems, a Danaher subsidiary, provides end-to-end anatomic pathology workflow solutions — histology, IHC/ISH staining, and Aperio digital pathology scanners with AI — to hospitals, biopharma CDx partners, and academic medical centers globally.

Ownership category

akta.pro rank

Product category

Anatomic Pathology Equipment & Digital Pathology Solutions

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Anatomic pathology equipment
• Digital pathology solutions
• IHC ISH staining instruments
• Tissue processing histology
• Companion diagnostics development

Headquarters

HQ city

Nußloch

HQ country

Germany

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Hardware & Instruments: One-time sale of capital equipment including Aperio digital pathology scanners (GT 450, GT Elite, GT 180 DX, CS5 DX, AT2 DX), BOND IHC/ISH stainers (BOND-III, BOND-MAX, BOND-PRIME, BOND RX), tissue processors (HistoCore PEGASUS, PELORIS, PEARL, ASP6025), microtomes, cryostats, slide stainers/coverslippers (HistoCore CHROMAX, SPECTRA CV/ST), and slide/cassette printers (Leica IP S, IP C, HistoCore PERMA S).
2. Consumables: Recurring revenue from histology consumables including slides & coverglass (PERMAFLEX, PERMASLIDE), paraffins, microtome and cryostat blades, cassettes, reagents and solutions, routine H&E and special stains, mounting media, and archiving/transport/storage products. Sold via shop.leicabiosystems.com.
3. IHC/ISH Primary Antibodies & Detection Systems: Recurring reagent revenue from IHC primary antibodies, detection systems, ancillaries and consumables, Kreatech FISH probes, and Novocastra ISH probes used on the BOND platform.
4. Digital Pathology Software & AI Subscriptions: Recurring and licensing revenue from Aperio digital pathology software (management and integration), Aperio iQC, Aperio HALO AP image management, and third-party AI algorithms distributed via the Aperio AI Store (research use only).
5. Companion Diagnostics (CDx) Development & Commercialization: Revenue from co-developed companion diagnostic assays with biopharma (e.g., BOND Oracle HER2 IHC, AstraZeneca/Daiichi Sankyo TROP2 NMR for NSCLC) including assay development, clinical trial execution, regulatory strategy, and commercial kit planning delivered through joint CDx development models.
6. Service & Support Contracts: Recurring service revenue through TechServices (Aperio products) and Tech.Support (all other products), keeping essential equipment operational across the installed base of 3000+ experts supporting customers globally.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Core offering

Leica Biosystems manufactures and sells end-to-end anatomic pathology laboratory workflow solutions — histology equipment (tissue processors, microtomes, cryostats, slide stainers/coverslippers), IHC/ISH staining instruments (BOND family), digital pathology whole-slide scanners (Aperio GT 450 DX, GT 180 DX, GT Elite, CS5 DX), AI-powered image analysis software (Aperio iQC, HALO AP, Aperio AI Store), companion diagnostic assay development services, and recurring histology/IHC consumables and reagents — for cancer diagnostics customers including hospitals, pathology laboratories, biopharma sponsors, and academic research centers.

Differentiator

Problem solved

Functional benefit

Brands

• Aperio: Digital pathology product line including whole slide scanners (Aperio GT 450, GT 450 DX, GT 180, GT 180 DX, GT Elite), Aperio AT2 DX, Aperio CS5 DX, Aperio iQC and iQC DX software, Aperio HALO AP image management software, and the Aperio AI Store for AI-powered image analysis.
• BOND
• HistoCore
• Novocastra
• Kreatech
• Mammotome

Products and services

• HistoCore CHROMAX WS Workstation Automated H&E staining and glass coverslipping workstation for clinical histology laboratories, designed for higher throughput, optimized reagent consumption, and modern GUI; for in vitro diagnostic use.
• BOND RX Fully Automated Research Stainer

Quantifiable outcome

• Processes 103 slides per hour at 22 seconds per slide (Aperio GT Elite)
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability7 records

Feature7 records

Partnerships

15 partnerships are on record, tiered core — listed as innovation partner on leicabiosystems.com/partners, flagship — global cdx co-development, flagship — ai biomarker scoring at clinical scale, flagship — global cdx expansion, core — global reseller of ai applications within aperio ecosystem, core — ai-ready pathology informatics platform, core — spatial biology research compatibility, flagship — parent company and danaher centers for enabling precision medicine partner, core — ai/digital pathology integration & fda compatibility, flagship — ultraplex technology integration, core — listed as innovation partner, major — european national digital pathology rollout and flagship — multiplex ihc technology integration.

• Molecular Instrumentscore — listed as innovation partner on leicabiosystems.com/partnersTechnology or Integration · 25 June 2026Released HCR™ Gold IF on the BOND RX research staining instrument, enabling automated multiplex immunofluorescence workflows for tissue analysis. Allows researchers to perform flexible multiplex protein detection using off-the-shelf primary antibodies on the established BOND RX automation platform, without requiring stripping workflows or custom antibody conjugations.
• AstraZeneca & Daiichi Sankyoflagship — global cdx co-developmentStrategic or Co-development Partner · 3 June 2026Strategic collaboration to develop an IHC assay and AI-powered image analysis algorithm for the TROP2 Normalized Membrane Ratio biomarker in non-small cell lung cancer. Combines AstraZeneca's Quantitative Continuous Scoring algorithm with Leica's digital pathology platforms (BOND RX stainer, Aperio GT 450 scanner, Aperio HALO AP image management); algorithm distributed globally via Aperio AI Store for research use only.
• Indica Labs & Lunitflagship — ai biomarker scoring at clinical scaleStrategic or Co-development Partner · 29 May 2026Three-way collaboration to develop AI image-analysis algorithms for PD-L1 and other IHC biomarkers in cancer research. Integrates Leica's IHC staining platform and Aperio GT 450 scanner, Indica Labs' Aperio HALO AP image management, and Lunit's SCOPE biomarker scoring algorithm into a single standardized workflow, available through Leica's Aperio AI Store.
• CellCartaflagship — global cdx expansionStrategic or Co-development Partner · 29 May 2026Strategic partnership to expand companion diagnostic (CDx) joint development model from China to global biopharma sponsors. Introduces a flexible, end-to-end CDx framework integrating assay development, clinical trial execution, regulatory strategy, and commercial kit planning, leveraging CellCarta's global laboratory network and CDx Bridge Model alongside Leica's digital pathology capabilities (Aperio Scanners and AI-enabled platforms).
• Mindpeakcore — global reseller of ai applications within aperio ecosystemChannel Partner/ Reseller/ Distributor · 19 March 2026Global reseller agreement under which Leica Biosystems becomes an authorized global reseller of Mindpeak's AI pathology applications within its Aperio digital pathology ecosystem. Initially offers nine AI applications for biomarker quantification and tissue analysis, covering Ki-67, HER2, ER/PR, p53, and PD-L1, enabling laboratories and biopharma teams worldwide to access AI-powered pathology tools.
• L7 Informaticscore — ai-ready pathology informatics platformTechnology or Integration · 24 November 2025Strategic partnership to develop an AI-ready pathology platform that integrates L7 Informatics' Enterprise Science Platform (L7|ESP) with Leica Biosystems' instrumentation. Addresses siloed data systems, rising diagnostic demands, and workforce shortages; commercial product availability expected in early 2026.
• Bio-Technecore — spatial biology research compatibilityTechnology or Integration · 28 October 2025Launched the ProximityScope™ assay, a spatial biology tool compatible with Leica Biosystems' BOND RX platform, designed to visualize protein-protein interactions within tissue samples. Showcased at the Society for Immunotherapy of Cancer meeting in November 2025.
• Danaher Corporationflagship — parent company and danaher centers for enabling precision medicine partnerStrategic or Co-development Partner · 29 May 2025Danaher announced a strategic partnership with AstraZeneca to develop and commercialize novel diagnostic tools for precision medicine, focusing on AI-powered diagnostics and digital pathology. The collaboration leverages Danaher's Centers for Enabling Precision Medicine and Leica Biosystems' digital pathology platform to deploy diagnostic solutions globally through Leica's international laboratory footprint.
• Paige (Paige.AI)core — ai/digital pathology integration & fda compatibilityStrategic or Co-development Partner · 22 April 2025Paige's FullFocus™ digital pathology image viewer received FDA 510(k) clearance for use with the Leica Aperio GT 450 DX scanner and Hamamatsu NanoZoomer S360MD Slide scanner. Paige and Leica Biosystems have a multi-year partnership spanning Foundation Model development and AI-enabled diagnostics, referenced in Paige.ai's 2024 outlook and Leica's 25-year CDx review.
• Cell IDx, Inc.flagship — ultraplex technology integrationStrategic or Co-development Partner · 8 November 2022Leica Biosystems acquired Cell IDx, Inc., a multiplexed tissue profiling technology company based in San Diego, on November 8, 2022. The acquisition enhances Leica's capabilities in translational research and cancer diagnostics through advanced multiplex immunohistochemistry technology, integrating Cell IDx's UltraPlex technology with Leica's BOND RX fully automated research stainer to facilitate high-throughput, multi-marker tissue analysis.
• Cell Signaling Technologycore — listed as innovation partnerTechnology or IntegrationStrategic collaboration cited in Leica Biosystems' 25-year CDx review to advance AI, digital pathology, and multiplexing technologies for future companion diagnostic development. Listed as Innovation Partner on leicabiosystems.com/life-sciences-and-research-solutions/partners/.
• Abcamcore — listed as innovation partnerTechnology or IntegrationListed as an Innovation Partner on the Leica Biosystems Life Sciences Partnerships page; antibody provider integrated into Leica's IHC/ISH workflows. Danaher Corporation acquired Abcam plc (referenced in ISH market context).
• Advanced Cell Diagnostics (ACD)core — listed as innovation partnerTechnology or IntegrationListed as an Innovation Partner on the Leica Biosystems Life Sciences Partnerships page for co-development of open platforms that automate tissue-based research workflows, including RNAscope ISH technologies.
• Leeds Teaching Hospitals NHS Trust & National Pathology Imaging Co-operativemajor — european national digital pathology rolloutImplementation/ SI/ Consulting PartnerIn partnership with Leica Biosystems, Leeds Teaching Hospitals NHS Trust completed its transition to fully digital pathology scanning in 2018, becoming part of the National Pathology Imaging Co-operative — the largest national integrated digital pathology network in Europe. The trust's verification and validation processes formed the foundation of UK Royal College of Pathologists guidelines for digital pathology.
• Cell IDx / UltraPlex technology (post-acquisition integration)flagship — multiplex ihc technology integrationStrategic or Co-development PartnerFollowing the 2022 acquisition of Cell IDx, Leica Biosystems integrates the UltraPlex technology into its BOND RX fully automated research stainer for advanced multiplex biomarker detection, particularly in clinical pathology and translational research.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hamamatsu Photonics: Closest direct competitor in digital pathology scanners (NanoZoomer series) and the #2 player in the digital pathology solution market at ~18% share per QYResearch. Competes head-to-head with Leica's Aperio GT 450, GT Elite, and GT 180 scanners in hospital and reference-lab deployments.
• 3DHISTECH: Hungarian digital pathology vendor offering Pannoramic slide scanners and CaseViewer software; competes with Leica's Aperio family in mid-volume labs and academic pathology, particularly in Europe and Asia.
• Sakura Finetek: Competes with Leica in histology tissue processing, embedding, and staining/coverslipping (e.g., Tissue-Tek VIP, Autostainer lines); overlapping installed base in hospital histology labs globally.
• Epredia (3DHISTECH/Pannoramic distribution): Anatomical pathology vendor formed from Thermo Fisher's histology business, distributing 3DHISTECH Pannoramic scanners and competing with Leica across histology consumables, slide printers, and digital pathology scanners in routine diagnostics.

Broad incumbents

• Roche Diagnostics (Ventana): Major competitor across IHC/ISH staining instruments (BenchMark series), primary antibodies, companion diagnostics, and digital pathology (uPath software). Offers integrated pathology workflow bundled into Roche's much larger diagnostics and pharma franchise; ~8% digital pathology share.
• Philips (IntelliSite Pathology Solution): Direct competitor in digital pathology scanners and image management, often bundled with Philips' broader hospital imaging informatics portfolio. Holds ~7% digital pathology market share and competes for large integrated delivery network and national-scale deals.

Emerging players

• Indica Labs: Provides HALO and HALO AP image management and AI analysis software widely used in research and clinical pathology; both a partner (integrated with Leica Aperio scanners) and a competitor for AI image analysis workloads that could be deployed scanner-agnostically.
• Paige.AI: AI-first digital pathology company whose FullFocus viewer is FDA 510(k)-cleared with the Leica Aperio GT 450 DX; a multi-year partner of Leica on foundation models and AI-enabled diagnostics, but also a competitor as Paige builds scanner-agnostic AI products.
• Akoya Biosciences: Spatial biology and multiplex IHC player (PhenoCycler, Opal chemistry) competing with Leica's UltraPlex (Cell IDx), BOND RX multiplex workflows, and HCR Gold IF collaborations in translational research and pharma biomarker work.

Others

• Roche / Danaher Diagnostics Segment comparables — Beckman Coulter, Bio-Techne: Bio-Techne is a spatial biology partner (ProximityScope on BOND RX) and an indirect competitive adjacent in protein reagents/assays that increasingly power pathology workflows. Useful as a comparand for the R&D reagent side of Leica's business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/LeicaBio
• YouTubeyoutube.com/user/LeicaBiosystems
• Facebookfacebook.com/LeicaBiosystems
• LinkedInlinkedin.com/company/leica-biosystems

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leica Biosystems